Neovasc Inc. (NVCN): Price and Financial Metrics


Neovasc Inc. (NVCN): $0.83

-0.02 (-2.85%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NVCN POWR Grades


  • NVCN scores best on the Sentiment dimension, with a Sentiment rank ahead of 71.31% of US stocks.
  • The strongest trend for NVCN is in Momentum, which has been heading down over the past 31 weeks.
  • NVCN ranks lowest in Quality; there it ranks in the 2nd percentile.

NVCN Stock Summary

  • Neovasc Inc's market capitalization of $23,692,782 is ahead of only 4.04% of US-listed equities.
  • As for revenue growth, note that NVCN's revenue has grown -79.42% over the past 12 months; that beats the revenue growth of merely 2.44% of US companies in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for NVCN comes in at -152.39% -- higher than that of just 1.65% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Neovasc Inc, a group of peers worth examining would be BGMD, ACRX, BXRX, MYOV, and ARDS.
  • NVCN's SEC filings can be seen here. And to visit Neovasc Inc's official web site, go to www.neovasc.com.

NVCN Valuation Summary

  • NVCN's EV/EBIT ratio is -0.7; this is 102.62% lower than that of the median Healthcare stock.
  • NVCN's EV/EBIT ratio has moved down 0.9 over the prior 165 months.
  • NVCN's EV/EBIT ratio has moved down 0.9 over the prior 165 months.

Below are key valuation metrics over time for NVCN.

Stock Date P/S P/B P/E EV/EBIT
NVCN 2020-01-17 5.4 -1.0 -0.1 -0.1
NVCN 2018-07-31 3.0 -0.4 -0.7 -0.8
NVCN 2017-02-09 9.1 1.6 -2.6 -1.0
NVCN 2017-01-13 12.3 2.1 -3.5 -1.9
NVCN 2008-12-18 1.8 0.6 -0.3 0.0
NVCN 2008-07-28 1.8 0.6 -0.3 0.0

NVCN Growth Metrics

  • Its year over year revenue growth rate is now at -6.44%.
  • Its 4 year net cashflow from operations growth rate is now at 26.01%.
  • Its 5 year net income to common stockholders growth rate is now at 18.29%.
Over the past 24 months, NVCN's revenue has gone up $208,229.

The table below shows NVCN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2020-12-31 1.957362 -29.44186 -28.69504
2019-12-31 2.092032 -23.97213 -35.13101
2018-12-31 1.749133 -22.79475 -108.0429
2017-12-31 5.389014 -138.6139 -22.90872
2016-12-31 9.512796 -39.79416 -86.49489
2015-12-31 9.92994 -21.28296 -35.11669

NVCN Price Target

For more insight on analysts targets of NVCN, see our NVCN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.00 Average Broker Recommendation 1.5 (Moderate Buy)

NVCN Stock Price Chart Interactive Chart >

Price chart for NVCN

NVCN Price/Volume Stats

Current price $0.83 52-week high $3.08
Prev. close $0.85 52-week low $0.68
Day low $0.82 Volume 620,800
Day high $0.84 Avg. volume 3,116,608
50-day MA $0.89 Dividend yield N/A
200-day MA $1.08 Market Cap 55.98M

Neovasc Inc. (NVCN) Company Bio


Neovasc is a specialty medical device company that develops, manufactures and markets products for the cardiovascular marketplace. The Company also sells a line of biological tissue products that are used as components in third-party medical products including transcatheter heart valves. The company was founded in 2000 and is based in Richmond, Canada.


NVCN Latest News Stream


Event/Time News Detail
Loading, please wait...

NVCN Latest Social Stream


Loading social stream, please wait...

View Full NVCN Social Stream

Latest NVCN News From Around the Web

Below are the latest news stories about Neovasc Inc that investors may wish to consider to help them evaluate NVCN as an investment opportunity.

Neovasc to Report Second Quarter 2021 Financial Results on August 10, 2021

VANCOUVER, July 27, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the second quarter ended June 30, 2021 on Tuesday, August 10 2021. Neovasc’s President and Chief Executive Officer, Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the Company’s results at 4:30 pm EDT. Interested parties may access the conference call by dialing (877)-407-9208 or (201)-493-6784 (International) and referen

Yahoo | July 27, 2021

Neovasc Announces New Appointments in Regulatory and Clinical Leadership

Neovasc Team Grows with Addition of Industry Veterans Lisa Becker as VP, Regulatory Affairs, Global Angina Therapies and Sarah Gallagher as VP of Clinical Affairs

Intrado Digital Media | July 13, 2021

Neovasc Inc.: Neovasc Announces New Appointments in Regulatory and Clinical Leadership

Neovasc Team Grows with Addition of Industry Veterans Lisa Becker as VP, Regulatory Affairs, Global Angina Therapies and Sarah Gallagher as VP of Clinical Affairs Vancouver, British Columbia and M

FinanzNachrichten | July 13, 2021

Neovasc Inc. (NVCN): Hedge Funds Are Snapping Up

Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock […]

Yahoo | June 23, 2021

Real World Study Shows Neovasc's Reducer Is Safe, Efficacious In Patients With Refractory Angina

Neovasc Inc (NASDAQ: NVCN) has announced the publication of an article highlighting the long-term outcomes of patients suffering from refractory angina treated with the Neovasc Reducer system in the International Journal of Cardiology. The study dubbed RESOURCE is an observational, retrospective registry that includes 658 patients in Europe, the U.K., and Israel. The prespecified endpoints of the trial were the amelioration of anginal symptoms, evaluated with chest pain severity score and the ra

Yahoo | June 18, 2021

Read More 'NVCN' Stories Here

NVCN Price Returns

1-mo N/A
3-mo -3.26%
6-mo -39.42%
1-year -69.14%
3-year -97.23%
5-year -99.88%
YTD -12.78%
2020 -82.41%
2019 -9.83%
2018 -99.00%
2017 -65.32%
2016 -61.56%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7397 seconds.